​​​
  1. A muted quarter for the company

A muted quarter for the company

STR reported muted Q4 with adj. EPS of Rs 1.9/sh (JEFe: 4.2). Revenues were 17% and margins 300bps below JEFe. US revenues were down 50% q-o-q ($21 mn vs $42 mn).

By: | New Delhi | Updated: May 26, 2018 12:58 AM

STR reported muted Q4 (EPS -50% vs JEFe) weighed down by weak US and Institutional business. Mgmt expects impact to continue in 1H but recovery from 2H. Given its leadership in Australia, steady ramp-up in developed markets and lower CHC (consumer health connections) spend along with expected recovery in US, we expect 35% Ebitda CAGR over FY19-20. Stock trading at 13x FY18e EV/Ebitda, does not factor in any recovery, and risk-reward is favourable. Retain Buy with new Rs 600 TP.

Subdued Q4: STR reported muted Q4 with adj. EPS of Rs 1.9/sh (JEFe: 4.2). Revenues were 17% and margins 300bps below JEFe. US revenues were down 50% q-o-q ($21 mn vs $42 mn).

Estimates:We adjust our model for the demerger/sale of API and India business and factor in the new outlook. Consequently our FY19-20 EPS falls by 60/48%. We cut our organic revenue estimates by 10% and margins by 300/180bps.

 

Valuations factoring in worst case: STR stock price has corrected 50%+YTD and now trades at 9x FY20PE, at 50% discount to sector. Trading at 13x FY18 EV/Ebitda it values the ex-Australia business at 1x EV/Sales implying no recovery. However, we expect better growth. We value STR at 14x FY20e PE, at 25% discount to peers.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top